Tag: DM4
FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), previously known as IMGN853, for the treatment of patients diagnosed...
ASCO 2022: SORAYA Study Shows Consistent Safety Profile for Mirvetuximab Soravtansine...
Mirvetuximab soravtansine, previously know as IMGN853, shows a tumor reduction in 71.4% of patients and preliminary median overall survival of 13.8 months in high folate receptor...
Anetumab Ravtansine Demonstrates Encouraging Preliminary Antitumor Activity in Heavily Pretreated Mesothelin-expressing...
In a phase I clinical trial, the investigational antibody-drug conjugate (ADC) anetumab ravtansine (BAY 94-9343; Bayer) shows promising antitumor activity in heavily pretreated patients with...
Oxford Bio Receives US Investigational New Drug Clearance for OBT076
The U.S Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for OBT076, an experimental antibody-drug conjugate or ADC being developed...
Anetumab Ravtansine does not meet Primary Endpoint in Second-Line Mesothelioma
A Phase II clinical trial evaluating its anetumab ravtansine, also known as BAY 949343, as a monotherapy in patients with recurrent malignant pleural mesothelioma...
ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers
With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...
